Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate

被引:36
作者
Xie Qing [1 ,2 ,3 ]
Wang Furong [4 ]
Liu Yunxia [5 ]
Zhang Jian [6 ]
Wang Xuping [7 ,8 ]
Gao Ling [1 ]
机构
[1] Shandong Univ, Prov Hosp, Dept Cent Lab, Jinan 250100, Peoples R China
[2] Shandong Univ, Dept Pharm, Qilu Hosp, Jinan 250100, Peoples R China
[3] Shandong Univ, Sch Med, Inst Pharmacol, Jinan 250100, Peoples R China
[4] Shandong Univ Tradit Chinese Med, Dept Pharmacol, Jinan, Peoples R China
[5] Shandong Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Jinan 250100, Peoples R China
[6] Shandong Univ, Qilu Hosp, Dept Clin Lab, Jinan 250100, Peoples R China
[7] Shandong Univ, Qilu Hosp, Chinese Minist Hlth, Jinan 250100, Peoples R China
[8] Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Remodeling & Funct Res, Chinese Minist Educ, Jinan 250100, Peoples R China
来源
CARDIOVASCULAR DIABETOLOGY | 2012年 / 11卷
基金
中国国家自然科学基金;
关键词
Cystatin C; Gensini score; Metabolic syndrome; Asymptomatic coronary artery disease; CARDIOVASCULAR RISK-FACTORS; LONG-TERM MORTALITY; RENAL-FUNCTION; HEART-DISEASE; CREATININE CLEARANCE; ASSOCIATION; IMPACT; EVENTS; MARKER; ATHEROSCLEROSIS;
D O I
10.1186/1475-2840-11-108
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: All of the components of Metabolic syndrome (MetS) have been regarded as risk factors for coronary artery disease (CAD). Early detection of CAD in asymptomatic patients with MetS remains a challenge. Cystatin C, which has been proposed as a novel marker of renal dysfunction, is correlated with mortality in CAD, The purpose of the study was to evaluate whether cystatin C is a potential marker of asymptomatic CAD in MetS patients with normal kidney function. Methods: A total of 211asymptomatic MetS patients without prior history of CAD patients were included in a cross-sectional study. Patients were divided into MetS with asymptomatic CAD (n = 136) and MetS without CAD (n = 75) groups according to coronary angiograph results. Serum cystatin C levels were measured using particle enhanced immunonephelometric assays. We first assessed whether there is an independent association of cystatin C with the presence and severity of asymptomatic CAD. Then, we investigated the association between cystatin C and other biochemical risk factors for atherosclerosis. Results: Serum cystatin C levels in patients with asymptomatic CAD were significantly higher than those without CAD (P = 0.004). A multiple logistic regression analysis demonstrated cystatin C was independently associated with the presence of asymptomatic CAD (OR = 1.326, 95% CI: 1.086-1.619). On receiver operating characteristics (ROC) analysis, the area under the curve (AUC) was 0.622 (95 % CI: 0543-0.701, P = 0.003), and cystatin C showed a moderate predictive value. Furthermore, cystatin C was independently correlated with Gensini score (standardized beta = 0.183, P = 0.007), and serum cystatin C levels increased with the increasing of number of disease vessels (P = 0.005). In a multiple stepwise regression analysis, uric acid (UA)(P < 0.001), body mass index (BMI)(P = 0.002), triglyceride(TG)(P = 0.03), estimated glomerular filtration rate (eGFR)(P < 0.001), and fibrinogen(P = 0.001) were independently associated with cystatin C. Conclusions: Serum cystatin C in our study was significantly associated with the presence and severity of asymptomatic CAD in MetS patients with normal kidney function, suggesting that cystatin C is probably more than a marker of glomerular filtration rate.
引用
收藏
页数:9
相关论文
共 41 条
  • [1] Association CM, 2004, CHINESE J DIABETES, V12, P156
  • [2] Bengtsson E, 2005, ATHEROSCLEROSIS, V180, P45, DOI [10.1016/j.atherosclerosis.2004.12.025, 10.1016/j.athersclerosis.2004.12.025]
  • [3] Bökenkamp A, 2002, CLIN CHEM, V48, P1123
  • [4] Prognostic significance of asymptomatic coronary artery disease in patients with diabetes and need for early revascularization therapy
    Choi, E.-K.
    Koo, B.-K.
    Kim, H.-S.
    Cho, Y.-M.
    Kang, H.-J.
    Cho, Y.-S.
    Chung, W.-Y.
    Chae, I.-H.
    Choi, D.-J.
    Oh, B.-H.
    Park, Y.-B.
    Choi, Y.-S.
    [J]. DIABETIC MEDICINE, 2007, 24 (09) : 1003 - 1011
  • [5] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [6] Cystatin C as a marker of GFR -: history, indications, and future research
    Filler, G
    Bökenkamp, A
    Hofmann, W
    Le Bricon, T
    Martínez-Brú, C
    Grubb, A
    [J]. CLINICAL BIOCHEMISTRY, 2005, 38 (01) : 1 - 8
  • [7] Impact of thyroid dysfunction on serum cystatin C
    Fricker, M
    Wiesli, P
    Brändle, M
    Schwegler, B
    Schmid, C
    [J]. KIDNEY INTERNATIONAL, 2003, 63 (05) : 1944 - 1947
  • [9] Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials
    Gibson, CM
    Dumaine, RL
    Gelfand, EV
    Murphy, SA
    Morrow, DA
    Wiviott, SD
    Giugliano, RP
    Cannon, CP
    Antman, EM
    Braunwald, E
    [J]. EUROPEAN HEART JOURNAL, 2004, 25 (22) : 1998 - 2005
  • [10] Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
    Grundy, SM
    Cleeman, JI
    Daniels, SR
    Donato, KA
    Eckel, RH
    Franklin, BA
    Gordon, DJ
    Krauss, RM
    Savage, PJ
    Smith, SC
    Spertus, JA
    Costa, F
    [J]. CIRCULATION, 2005, 112 (17) : 2735 - 2752